BMY - Jounce Therapeutics: An Undervalued Biotech Flush With Big Pharma Cash
Jounce Therapeutics (JNCE) is a small biotechnology company focused on the rapidly expanding industry of immuno-oncology. Armed with a productive drug discovery platform, a unique mid-stage lead candidate in lung cancer, and a penchant for striking lucrative deals with big pharma, the future looks bright for Jounce Therapeutics. What's more, with the stock having retraced significantly after initially rising on a major partnership deal with Gilead Sciences (GILD), the future looks similarly bright for JNCE investors.
Jounce Therapeutics: Background and Overview
Jounce Therapeutics specializes in treating cancer through a relatively new